Gsk (GSK) Change in Cash (2009 - 2026)

Gsk (GSK) has 18 years of Change in Cash data on file, last reported at -$404.1 million in Q3 2026.

• For the quarter ending Q3 2026, Change in Cash changed N/A year-over-year to -$404.1 million; the trailing twelve-month figure through Sep 2026 stood at $550.5 million (changed N/A YoY), and the FY2025 full-year result was -$235.4 million, down 130.75% from the prior year.
• Change in Cash was -$404.1 million for Q3 2026 at Gsk, down from -$71.5 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $9.3 billion in Q1 2022 to a low of -$818.0 million in Q1 2023.
• A 5-year average of $1.3 billion and a median of -$63.7 million in 2025 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash soared 716.27% in 2022 and plunged 190.68% in 2025, its largest moves.
• Gsk's Change in Cash stood at $4.1 billion in 2022, then tumbled by 108.97% to -$371.1 million in 2023, then jumped by 116.6% to $61.6 million in 2024, then plunged by 190.68% to -$55.9 million in 2025, then tumbled by 623.39% to -$404.1 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were -$404.1 million in Q3 2026, -$71.5 million in Q1 2026, and -$55.9 million in Q4 2025.